Medium Risk

LAURUS LABS LIMITED

Development manufacturing and services Chemical and Chemical products,Pharmaceuticals Medicinal Chemical, Bio and Botani

CIN: L24239AP2005PLC047518 FY: - Revenue: ₹5,127.0 Cr
5.4
ESG Risk
Score /10
Compliance RiskEpr ExposureGhg Intensity

Risk Breakdown

GHG Intensity
5.0
Water Intensity
5.0
Waste Intensity
1.9
EPR Exposure
6.5
Compliance Risk
10.0
HR Risk
3.0
Governance Risk
3.0

Financial Exposure

Est. Compliance Cost₹8–31 crore
EPR ApplicableUnknown
Scope 1 Emissions— tCO2e
Scope 2 Emissions— tCO2e
Water Withdrawal— m³
Waste Generated53,734.3 T

Governance

Anti-Corruption PolicyYes
Conflict of Interest PolicyYes
BRSR AssurancePartial
Assurance ProviderLLP

Double Materiality

Financial Materiality5.4
Impact Materiality4.8
QuadrantFinancially Material

Supply Chain

MSME Sourcing0.1%
Lifecycle AssessmentNo
Product ReclaimYes

Material Risks

e-waste

ESG Targets & Commitments

TopicTarget / MetricStatus
Human Rights in Supply Chain HR clauses in all contracts Commitment

AI Risk Summary

**LAURUS LABS LIMITED – FINANCIAL RISK SUMMARY** Laurus Labs faces critical compliance exposure with a 10.0/10 compliance risk score and estimated remediation costs of ₹8–31 crore, driven primarily by Extended Producer Responsibility (EPR) obligations under Indian packaging and chemical waste rules—a mandatory requirement for pharmaceutical manufacturers that remains unresolved. The company's missing Scope 1 and Scope 2 emissions data, combined with unknown EPR applicability status, creates immediate SEBI BRSR disclosure non-compliance risk, potentially triggering enforcement action and delisting implications for a ₹5,127 crore revenue entity. Medium GHG and water intensity risks (5.0/10 each) suggest latent carbon liability; at India's ₹600–900/tonne CO2e carbon pricing benchmark, unquantified operational emissions could generate significant future costs if carbon regulations tighten or internal pricing mechanisms are implemented. Priority remediation: establish baseline emissions inventory, clarify EPR regulatory obligations under chemical/pharma waste rules, and quantify compliance cost drivers to mitigate enforcement and market

Source: LAURUS LABS LIMITED BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.

← Back to ESG Quotient Dashboard Share on LinkedIn Browse all companies →